Research library

Key finding

In SURMOUNT-1, weekly tirzepatide reduced mean body weight by 15.0% to 20.9% at 72 weeks versus 3.1% with placebo.

Key finding

In adults with obesity and type 2 diabetes, tirzepatide reduced mean body weight by 12.8% to 14.7% at 72 weeks versus 3.2% with placebo.

Key finding

After a 20.9% lead-in weight reduction, continued tirzepatide produced further loss while switching to placebo led to substantial weight regain.

Key finding

Over three years, tirzepatide produced sustained weight reduction and markedly lowered progression from prediabetes to type 2 diabetes versus placebo.

Key finding

A network meta-analysis of 28 randomized trials compared tirzepatide with semaglutide and ranked higher tirzepatide doses among the strongest options for HbA1c and weight reduction.

Key finding

The study reports that in patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).

Key finding

Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).

Key finding

66 (14%) participants discontinued the study drug and 50 (10%) discontinued the study prematurely.

Key finding

The study reports that lower baseline PF was associated with a higher prevalence of ORCs.

Key finding

The study reports that once-weekly treatment with tirzepatide demonstrated significant reductions in body weight and prespecified cardiometabolic measures compared with placebo in Japanese adults with obesity or overweight.

Key finding

The study reports that across both studies (N = 2384), ERs were more likely to be female, White and to have lower baseline HbA1c levels.

Key finding

The study reports that tirzepatide treatment was associated with improved HRQoL compared to placebo in people with overweight or obesity.

Key finding

The study reports that the CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss.

Key finding

The study reports that higher doses of tirzepatide, younger age, and female sex were associated with a longer TTWP.

Key finding

The study reports that in SURMOUNT-1, tirzepatide-associated improvements in cardiometabolic risk factors positively related to the degree of weight reduction, but the pattern varied depending on outcome measure.

Key finding

The study reports that higher doses of tirzepatide were associated with higher proportions of participants achieving various weight reduction thresholds at Weeks 24 and 72.

Key finding

The study reports that in this post hoc analysis, participants with early- versus later-onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP.

Key finding

The study reports that in this post hoc analysis, improvements in HbA1c and weight loss were consistent and significantly higher with tirzepatide, regardless of baseline β-cell function and insulin resistance, compared with semaglutide.

Key finding

The study reports that tirzepatide treatment was associated with a rapid decline in systolic and diastolic blood pressure over the first 24 weeks, followed by blood pressure stabilisation until the end of the observation period, resulting in a significant net reduction by 72 weeks of 6.8 mm Hg.

Key finding

The study reports that tirzepatide treatment significantly reduced the 10-year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.